VASC Vascular Solutions, Inc. featured news, full reports, and detailed charts
Vascular Solutions, Inc. (VASC) Wrap Up:
Vascular Solutions, Inc. (we, us or Vascular) is a medical device company focused on bringing clinically advanced solutions to interventional cardiologists and interventional radiologists worldwide. We were incorporated in the state of Minnesota in December 1996, and we began operations in February 1997. Our main product lines consist of the following: • Hemostat (blood clotting) products, principally consisting of the D-Stat Dry™ hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat® Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets, • Extraction catheters, principally consisting of the Pronto® V3 extraction catheter, a mechanical system for the removal of soft thrombus from arteries, • Vein products, principally cons ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f05%2f0000897101-08-000253.html#FIS_BUSINESS"www.vascularsolutions.com
252 Employees
Founded in 1996
Vascular Solutions Inc. (VASC:NASDAQ)
LAST $8.08 USD
CHANGE TODAY +0.09 1.13%
VOLUME 31.8K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Vascular Solutions Inc. (VASC)
|
OPEN
$7.97
|
PREVIOUS CLOSE
$7.99
|
|
|
DAY HIGH
$8.11
|
DAY LOW
$7.97
|
|
|
52 WEEK HIGH
10/13/09 - $9.80
|
52 WEEK LOW
03/2/09 - $5.04
|
|
|
MARKET CAP
132.5M
|
AVERAGE VOLUME 3 mo
53.2K
|
|
|
DILUTED EPS TTM
$1.12
|
SHARES OUTSTANDING
16.4M
|
|
|
VASC Does Not Pay Dividends
|
P/E TTM
7.2x
|
|
| K = Thousands M = Millions B = Billions | ||
VASC Top Compensated Officers
Mr. Howard C. Root
Co-Founder, Chief Executive Officer and Direc...
Age: 48
Total Annual Compensation: $330.0K
Mr. James Hennen
Chief Financial Officer, Vice President of Fi...
Age: 36
Total Annual Compensation: $200.0K
Mr. James Quackenbush
Vice President of Manufacturing
Age: 50
Total Annual Compensation: $195.0K
Mr. Brett Demchuk
Vice President of Quality
Age: 45
Total Annual Compensation: $163.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Vascular Solutions Inc. (VASC)
Vascular Solutions Announces 510(k) Clearance and U.S. Launch of GuideLiner Catheter
11/9/2009
Vascular Solutions Inc. announced that it has received 510(k) clearance from the U.S. Food & Drug Administration to launch the GuideLiner(TM) catheter in the United States. The GuideLiner is a unique coaxial 'mother and child' guide extension with rapid exchange convenience that provides back-up support and selective deep intubation in challenging coronary interventions. The GuideLiner catheter will be available in 6, 7 and 8 French sizes as part of Vascular Solutions' specialty catheter product line. CE mark clearance of the GuideLiner was received and European sales and clinical uses commenced in October, with the U.S. launch of the GuideLiner catheter expected to commence in November through Vascular Solutions' direct sales force.
Vascular Solutions Inc. - Conference Presentation Call
11/3/2009
Vascular Solutions Inc. - Conference Presentation Calls
Vascular Solutions Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2009 ; Provides Earnings Guidance for the Fourth Quarter of 2009 and for the Year 2010
10/20/2009
Vascular Solutions Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. Net income for the third quarter was $1,431,000 or $0.09 per diluted share compared to net income of $1,722,000 or $0.11 per diluted share in the third quarter of 2008. Net income for the third quarter of 2009 included $407,000 of non-cash stock-based compensation and $746,000 of non-cash income tax expense based on a 34% tax rate, offset by the utilization of net operating loss carryforwards. Total revenue was $17,228,000 against $15,465,000 in 2008. Operating income was $2,178,000 against $1,748,000 in 2008. Income before tax was $2,177,000 against $1,744,000 in 2008. For the nine months, the company reported net income of $3,755,000 or $0.23 per diluted share compared to net income of $1,489,000 or $0.09 per diluted share in 2008. Total revenue was $50,205,000 against $44,818,000 in 2008. Operating income was $5,939,000 against $1,557,000 in 2008. Income before tax was $5,949,000 against $1,651,000 in 2008. Regarding future guidance, net revenue for the fourth quarter of 2009 is expected to be between $17.9 million and $18.3 million. Corresponding net income in the fourth quarter of 2009 on a fully-taxed basis is expected to be between $0.09 and $0.11 per fully diluted share. Looking into 2010, the company believes that will continue to grow sales by between 11% and 13% over 2009's levels, with net income accelerating by an even higher percentage.
VASC Competitors
| Company | Last | Change |
| biolitec | €3.98 EUR | 0.00 |
| Endologix Inc | $4.25 USD | +0.05 |
| Kensey Nash Corp | $23.30 USD | +0.10 |
| LeMaitre Vascular Inc | $4.88 USD | +0.13 |
| Spectranetics Corp | $6.01 USD | +0.16 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | VASC | Industry Range |
| Price/Earnings | 7.1x |
|
| Price/Sales | 1.9x |
|
| Price/Book | 3.5x |
|
| Price/Cash Flow | 7.1x |
|
| TEV/Sales | 1.8x |
|
|
VASC |
||
|
VASC transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Vascular Solutions, Inc.
More news for VASC
Vascular Solutions Announces Third Quarter Results; Net Revenue Increases 11% to Record $17.2 Million; Net Income of $0.09 Per Share
MINNEAPOLIS, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC - News) today reported financial results for the third quarter ended September 30, 2009. Highlights of the third quarter and other recent events include: * Achieved record net revenue of $17.2 million, an increase of 11% from the third quarter of 2008. * Achieved net income of $1,431,000, or $0.09 per diluted share. * Achieved positive cash flow of $3.5 million. * Increased operating margin to 13% of net revenue. * Launched the new Piggyback(TM) wire converter in the U.S. and the new GuideLiner(TM) catheter in Europe, with four additional new products including the Guardian(R) II hemostasis valve expected to be launched in the U.S. during the remainder of 2009. Commenting on the results, Vascular Solutions' Chief Executive Officer Howard Root said: "Once again, in the third quarter Vascular Solutions demonstrated double digit percentage sales growth and rapid new product innovation, while at the same time adding substantially to our net income and positive cash flow. As we conclude 2009, we are well on our way to our sixth consecutive year of double digit percentage sales growth, and we have clearly demonstrated the success of our business model in driving increased earnings from every incremental sale." Gross margin across all product lines was 66.0% in the third quarter of 2009, equivalent to 66.0% in the third quarter of 2008. Based on the projected product sales mix, gross margin o...Click here to read the whole Article (external link)
Q3 2009 Vascular Solutions, Inc. Earnings Release - After Market Close
Earnings Announcements for Tuesday, October 20CompanySymbolTimeConferenceCallAccess National CorporationANCXTime Not SuppliedAEOLUS TYRE CO600469.SSTime Not SuppliedALLEGIANT TRAVEL COALGTTime Not SuppliedAMERICAN CAPITAL AGENCY CORPAGNCAfter Market CloseListenAmeriServ Financial, Inc.ASRV08:00 am ETAmylin Pharmaceuticals, Inc.AMLNAfter Market CloseApplied Industrial TechnologiesAITBefore Market OpenArbitron Inc.ARBBefore Market OpenListenAstec IndustriesASTE07:00 am ETAutolivALV06:00 am ETAutonomy Corporation plcAUTNF.PKBefore Market OpenAware, IncAWRETime Not SuppliedListenBancFirstBANFBefore Market OpenBANK MUTUAL CORP NEWBKMUTime Not SuppliedBank of New York Mellon CorpBK06:30 am ETListenBanner CorporationBANRAfter Market CloseBEIJING SHUNXIN AGRICULTURE CO...Click here to read the whole Article (external link)
Vascular Solutions Inc. Q3 2009 Earnings Call Transcript
Vascular Solutions Inc. (VASC) Q3 2009 Earnings Call October 20, 2009; 04:30 pm ET Executives Howard Root - Chief Executive Officer James Hennen - Chief Financial Officer Analysts Christopher Warren - Caris & Co. Ernie Andberg - Feltl & Co. Chris Welniak - Canaccord Adams Chris Cooley - FTN Equity Capital Markets Jeff Jonas - Gabelli & Co. Jason Mills - Canaccord Adams Presentation Operator Good afternoon and welcome to Vascular Solutions third quarter conference call. At this all participants are in a listen-only mode. Later we will conduct a question-and-answer session; instructions will be given at the time. (Operator Instructions) I would now like to turn the conference over to Mr. Howard Root, CEO of Vascular Solutions. Mr. Root, please go ahead. Howard Root Thank you. Good afternoon everyone and welcome to Vascular Solutions third quarter conference call. Joining me today is James Hennen, our Chief Financial Officer. This conference call is being webcast to the public and is completely open to members of the media. Vascular Solutions shareholders and other interested parties. After our remarks, we will open up the call to questions. First, the necessary preamble, today’s conference call is a proprietary Vascular Solutions presentation and is being recorded by Vascular Solutions. No other recording, reproduction, transmission or distribution of today’s call is permitted without Vascular Solutions consent. This call is being audio simulcast on the internet via our company website at www.vascularsolutions.com. A replay of the conference call will be available on the internet shortly after the call is conclu...Click here to read the whole Article (external link)
Vascular Solutions, Inc. Earnings Call scheduled for 4:30 pm ET today
Call DetailsVascular Solutions, Inc. Earnings Conference Call (Q3 2009)Tue, Oct 20, 2009, 4:30 pm EasternAbout Vascular Solutions, Inc. (NasdaqGM:VASC)Vascular Solutions, Inc., a medical device company, develops solutions to interventional cardiologists and interventional radiologists worldwide. It provides Hemostat products, including D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding; and D-Stat Flowable hemostat, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. The company also offers extraction catheters consisting of Pronto V3 extraction catheter, a mechanical system for the removal of soft thrombus from arteries; Vein products, including Vari-Lase endovenous laser, a laser and procedure kit that is used for the treatment of varicose veins; and specialty catheters, such as Langston dual lumen catheters, Twin-Pass dual access catheter, Gandras catheters, and Gopher support catheters for clinical niches. In addition, it provides access products, which include Micro Elite and Expro Elite snares, the Guardian hemostasis valve, and guidewires used in connection with percutaneous access to the vasculature. Further, the company offers Acolysis ultrasound thrombolysis system for the treatment of peripheral vascular diseases in the international markets. Vascular Solutions, Inc. offers its products directly to the physicians through direct domestic sales force and international distribution network. The company was founded in 1996 and is based in Minneapolis, Minnesota.More Info:Quote |Chart |News |Profile |...Click here to read the whole Article (external link)
VASCULAR SOLUTIONS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
Show all filings for VASCULAR SOLUTIONS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VASCULAR SOLUTIONS INC 20-Oct-2009Results of Operations and Financial Condition, Financial Statements and Ex Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information p...Click here to read the whole Article (external link)
Vascular Solutions to Present at the 3rd Annual Canaccord Adams Cardiovascular Conference
Vascular Solutions to Present at the 3rd Annual Canaccord Adams Cardiovascular Conference - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; t...Click here to read the whole Article (external link)
VASCULAR SOLUTIONS INC Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue17,229 17,165 15,811 16,403 Cost of Revenue5,363 5,937 5,398 6,415 Gross Profit11,866 11,228 10,413 9,988 Operating ExpensesResearch Development1,988 1,803 1,916 1,783 Selling General and Administrative7,699 7,178 6,984 6,747 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss2,179 2,247 1,513 1,458 Income from Continuing OperationsTotal Other Income/Expenses Net8 21 11 29 Earnings Before Interest And Taxes2,187 2,268 1,524 1,487 Interest Expense10 11 9 10 Income Before Tax2,177 2,257 1,515 1,477 Income Tax Expense746 871 577 (13,207)Minority Interest - - - - Net Income From Continuing Ops1,431 1,386 938 14,684 Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes ...Click here to read the whole Article (external link)
Vascular Solutions Announces 510(k) Clearance and U.S. Launch of GuideLiner Catheter
MINNEAPOLIS, Nov. 9, 2009 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC - News) today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration to launch the GuideLiner(TM) catheter in the United States. The GuideLiner is a unique coaxial "mother and child" guide extension with rapid exchange convenience that provides back-up support and selective deep intubation in challenging coronary interventions. The GuideLiner catheter will be available in 6, 7 and 8 French sizes as part of Vascular Solutions' specialty catheter product line. CE mark clearance of the GuideLiner was received and European sales and clinical uses commenced in October, with the U.S. launch of the GuideLiner catheter expected to commence in November through Vascular Solutions' direct sales force. Dr. Douglas Fraser, an Interventional cardiologist with Manchester Heart Centre in Manchester, United Kingdom, commented on his initial clinical experience with the GuideLiner: "Deep intubation of the GuideLiner catheter within a soft 6F guide provides better backup support and is less traumatic than using stiff 7F and 8F guides that were previously required in complex disease. Furthermore, the soft and very flexible tip will often cross tortuous disease where a stent gets stuck, enabling delivery of stents and other equipment directly to the target lesion. The GuideLiner is as easy to insert as a standard rapid exchange balloon catheter and has quickly become a routine part of my angioplasty practice." ...Click here to read the whole Article (external link)
Vascular Solutions gets FDA approval for catheter product
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | ...Click here to read the whole Article (external link)
Would you like to leave a comment about Vascular Solutions, Inc. VASC
Find out what social network information about Vascular Solutions, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Vascular Solutions, Inc. there is more great information available at Realpennies.com